



*Patient Focused. Discovery Driven.*

## Exagen Diagnostics to Present at The Piper Jaffray 30<sup>th</sup> Annual Healthcare Conference

Leader in autoimmunity testing to present at upcoming investor conference

ALBUQUERQUE, NM and SAN DIEGO, CA, Nov 13, 2018 (GLOBE NEWSWIRE) - Exagen Diagnostics, a leader in autoimmune life sciences, today announced that it will present at the Piper Jaffray 30<sup>th</sup> Annual Healthcare Conference, which is being held Nov. 27-29 at the Lotte New York Palace in New York.

Ron Rocca, President and CEO, will present an overview of the patented cell-bound complement activation products (CB-CAPs) technology and other recent advances for the AVISE<sup>®</sup> brand of testing on Wednesday, November 28 at 10:50 a.m. ET.

### About Exagen Diagnostics

Exagen Diagnostics is a commercial stage life sciences company that is patient focused, and discovery driven. Exagen serves patients and healthcare providers across the U.S. in the diagnosis, prognosis, and management of lupus, rheumatoid arthritis, and other autoimmune conditions. By leveraging our patented and validated CB-CAPs technology we can help get to the real cause of a patient's symptoms and guide their journey to improved health. For more information visit, [www.exagen.com](http://www.exagen.com) or follow us on [Facebook](#), [Twitter](#), [YouTube](#), [LinkedIn](#), or [Instagram](#).

Investor Contact:  
Kamal Adawi  
Chief Financial Officer of Exagen Diagnostics, Inc.  
760.477.5514  
[IR@exagen.com](mailto:IR@exagen.com)